Drug-Food Interactions Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Drug-Food Interactions. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Drug-Food Interactions Indian Medical PG Question 1: Safe injection strategy will reduce the occurrence of:
- A. Hepatitis E
- B. Hepatitis A
- C. Hepatitis B (Correct Answer)
- D. Typhoid
Drug-Food Interactions Explanation: ***Hepatitis B***
- **Hepatitis B** is a blood-borne virus commonly transmitted through contaminated needles and syringes.
- Implementing **safe injection strategies**, such as using sterile equipment and proper disposal, effectively reduces its transmission.
*Hepatitis E*
- **Hepatitis E** is primarily transmitted via the **fecal-oral route**, often through contaminated water.
- It is not typically associated with unsafe injection practices.
*Hepatitis A*
- **Hepatitis A** is also spread primarily through the **fecal-oral route**, often from contaminated food or water.
- It has no significant link to injection safety practices.
*Typhoid*
- **Typhoid fever** is caused by *Salmonella Typhi* and is transmitted through the **ingestion of contaminated food or water**.
- Injection practices do not play a role in its transmission.
Drug-Food Interactions Indian Medical PG Question 2: A factor that is likely to increase the duration of action of a drug that is partially metabolized by CYP3A4 in the liver is:
- A. Chronic administration of phenobarbital with the drug
- B. Displacement from tissue binding sites by another drug
- C. Chronic administration of rifampicin
- D. Chronic administration of cimetidine with the drug (Correct Answer)
Drug-Food Interactions Explanation: ***Chronic administration of cimetidine with the drug***
- **Cimetidine** is a potent inhibitor of various **cytochrome P450 (CYP450) enzymes**, including **CYP3A4**.
- By inhibiting the metabolism of a drug predominantly metabolized by **CYP3A4**, cimetidine will increase its plasma concentration and extend its **duration of action**.
*Chronic administration of phenobarbital with the drug*
- **Phenobarbital** is a strong **inducer of CYP450 enzymes**, including **CYP3A4**.
- Induction would accelerate the metabolism of the drug, thus **decreasing its duration of action**, not increasing it.
*Displacement from tissue binding sites by another drug*
- Displacement from tissue binding sites would primarily increase the **free fraction of the drug in the plasma**, leading to a more rapid distribution to eliminating organs and potentially **shorter duration of action** if elimination is extraction-limited.
- This mechanism does not directly impact the **metabolic rate** unless clearance is significantly altered through increased availability for metabolism.
*Chronic administration of rifampicin*
- **Rifampicin** is a potent **inducer of CYP3A4** and other CYP enzymes.
- Its administration would lead to **increased metabolism** of the co-administered drug, thereby **reducing its duration of action**.
Drug-Food Interactions Indian Medical PG Question 3: Which of the following medications does not interact with warfarin?
- A. Barbiturate
- B. Oral contraceptive
- C. Cephalosporins
- D. Benzodiazepines (Correct Answer)
Drug-Food Interactions Explanation: ***Benzodiazepines***
- **Benzodiazepines** are generally considered safe to use with warfarin as they are extensively metabolized in the liver, but they do not typically alter the **cytochrome P450 enzymes** responsible for warfarin metabolism.
- They also do not interfere with **vitamin K recycling** or **platelet function**, which are key mechanisms through which other drugs interact with warfarin.
*Barbiturate*
- **Barbiturates** are **potent inducers of hepatic enzymes**, particularly CYP2C9, which is responsible for metabolizing warfarin.
- This enzyme induction leads to **increased warfarin metabolism**, reducing its anticoagulant effect and necessitating higher warfarin doses.
*Oral contraceptive*
- **Oral contraceptives** can **reduce the anticoagulant effect of warfarin** by inducing clotting factors or inhibiting warfarin metabolism.
- This interaction can increase the risk of **thromboembolic events** in patients on warfarin.
*Cephalosporins*
- Certain **cephalosporins**, especially those with a **methylthiotetrazole (MTT) side chain** (e.g., Cefamandole, Cefoperazone, Moxalactam), can **inhibit vitamin K epoxide reductase**.
- This inhibition leads to a **decrease in vitamin K-dependent clotting factors**, thus potentiating the anticoagulant effect of warfarin and increasing bleeding risk.
Drug-Food Interactions Indian Medical PG Question 4: Which drug should not be given with ketoconazole?
- A. Indinavir (Correct Answer)
- B. Macrolide
- C. All of the options
- D. Aminoglycoside
Drug-Food Interactions Explanation: ***Correct: Indinavir***
- **Indinavir** is a **protease inhibitor (antiretroviral)** that is primarily metabolized by **CYP3A4**
- **Ketoconazole** is a **potent CYP3A4 inhibitor** that significantly increases indinavir plasma concentrations
- Co-administration leads to **increased risk of indinavir toxicity** including nephrolithiasis, hyperbilirubinemia, and hepatotoxicity
- **Dose reduction of indinavir is required** if concurrent use is necessary (typically reduce to 600 mg q8h from 800 mg q8h)
*Incorrect: Macrolide*
- Many **macrolides** (erythromycin, clarithromycin) are CYP3A4 substrates and can interact with ketoconazole
- While caution is advised due to **QT prolongation risk**, this interaction is less severe than with indinavir
- Not an absolute contraindication but requires monitoring
*Incorrect: Aminoglycoside*
- **Aminoglycosides** (gentamicin, amikacin, tobramycin) are **NOT metabolized by CYP450 enzymes**
- They are **hydrophilic** and eliminated **unchanged by renal excretion**
- **No clinically significant interaction** with ketoconazole
- Can be safely co-administered without dose adjustment
*Key Learning Point*
- Ketoconazole inhibits CYP3A4, affecting metabolism of many drugs including **protease inhibitors, calcium channel blockers, statins, and some macrolides**
- Always check for CYP3A4 substrate drugs when prescribing azole antifungals
Drug-Food Interactions Indian Medical PG Question 5: The anticoagulant activity of warfarin can be reduced by all of the following except.
- A. Aspirin (Correct Answer)
- B. Rifampin
- C. Vitamin K
- D. Carbamazepine
Drug-Food Interactions Explanation: ***Aspirin***
- **Aspirin** does NOT reduce warfarin's anticoagulant activity; instead, it increases the risk of bleeding through a synergistic effect.
- Aspirin inhibits platelet aggregation via **cyclooxygenase-1 (COX-1)** inhibition, preventing thromboxane A2 formation, which is a different mechanism from warfarin's inhibition of vitamin K-dependent clotting factors.
- When combined with warfarin, aspirin **potentiates** the overall antithrombotic effect and increases bleeding risk.
*Carbamazepine*
- **Carbamazepine** is a potent inducer of hepatic cytochrome P450 enzymes (CYP2C9, CYP3A4).
- By increasing warfarin metabolism, it **reduces** warfarin's plasma concentrations and decreases its anticoagulant effect.
- Patients on this combination may require higher warfarin doses to maintain therapeutic INR.
*Rifampin*
- **Rifampin** is one of the most potent inducers of hepatic cytochrome P450 enzymes (CYP2C9, CYP3A4).
- It significantly increases warfarin metabolism, leading to **reduced** plasma concentrations and diminished anticoagulant effect.
- This interaction often necessitates substantial increases in warfarin dosage.
*Vitamin K*
- **Vitamin K** is the direct antagonist of warfarin's mechanism of action.
- Warfarin inhibits vitamin K epoxide reductase, preventing the regeneration of active vitamin K needed for synthesis of clotting factors II, VII, IX, and X.
- Administration of vitamin K **reverses** warfarin's anticoagulant effect by bypassing the inhibited enzyme and restoring clotting factor production.
Drug-Food Interactions Indian Medical PG Question 6: In patients taking tadalafil, the most serious drug interaction occurs with:
- A. Alpha-Blockers
- B. Ketoconazole
- C. Rifampicin
- D. Nitrates (Correct Answer)
Drug-Food Interactions Explanation: ***Nitrates***
- The co-administration of **tadalafil** (a PDE5 inhibitor) with **nitrates** can cause a dangerous and potentially fatal drop in **blood pressure**.
- Both drug classes lead to increased cGMP levels, resulting in excessive **vasodilation** and profound **hypotension**.
*Alpha-Blockers*
- Alpha-blockers, while able to cause **hypotension** when taken with tadalafil, generally lead to less severe interactions than nitrates.
- The combination requires caution and potentially dose adjustments, but typically does not result in the same life-threatening blood pressure drops as seen with nitrates.
*Ketoconazole*
- **Ketoconazole** is a strong **CYP3A4 inhibitor**, which can increase the plasma concentration of tadalafil.
- This interaction can potentiate tadalafil's effects and increase the risk of side effects, but it doesn't create an immediate, life-threatening hypotensive crisis like nitrates.
*Rifampicin*
- **Rifampicin** is a potent **CYP3A4 inducer**, which can significantly decrease the plasma concentration of tadalafil.
- This interaction primarily leads to a **reduced efficacy** of tadalafil, rather than a dangerous increase in adverse effects or a severe drug-drug interaction.
Drug-Food Interactions Indian Medical PG Question 7: Which of the following DPP-IV inhibitors is safe for use in chronic kidney disease patients without requiring dose modification?
- A. Sitagliptin
- B. Vildagliptin
- C. Linagliptin (Correct Answer)
- D. Saxagliptin
Drug-Food Interactions Explanation: ***Linagliptin***
- Unlike other **DPP-IV inhibitors**, **linagliptin** is primarily eliminated via **biliary/fecal excretion** (~85%) rather than renal excretion.
- This unique elimination pathway makes it **safe** for use in patients with **chronic kidney disease** at its usual dose, without the need for dose adjustment.
- It is the **only DPP-IV inhibitor** that does not require dose modification in CKD.
*Sitagliptin*
- **Sitagliptin** is primarily eliminated by the **kidneys** (~80% renal excretion), requiring **significant dose adjustments** in patients with **renal impairment**.
- Without dose modification, there is an increased risk of **drug accumulation** and adverse effects in CKD patients.
*Vildagliptin*
- **Vildagliptin** undergoes **hydrolysis** with subsequent **renal excretion** of inactive metabolites, requiring **dose reduction** in patients with moderate to severe **renal impairment**.
- Not recommended in severe renal impairment (eGFR <50 mL/min).
*Saxagliptin*
- **Saxagliptin** is partially eliminated via **renal excretion** and requires **dose reduction** by 50% in patients with moderate to severe **CKD**.
- Both parent drug and active metabolite accumulate in renal impairment, necessitating dose adjustment.
Drug-Food Interactions Indian Medical PG Question 8: Which of the following combinations can result in severe toxicity due to inhibition of cytochrome P450 enzymes?
- A. Amiodarone + Atorvastatin
- B. Carbamazepine + Atorvastatin
- C. Atorvastatin + Itraconazole (Correct Answer)
- D. Phenytoin + Atorvastatin
Drug-Food Interactions Explanation: ***Atorvastatin + Itraconazole***
- **Itraconazole** is a potent inhibitor of **CYP3A4**, the primary enzyme responsible for atorvastatin's metabolism.
- Co-administration leads to significantly increased **atorvastatin plasma concentrations**, raising the risk of severe side effects like **rhabdomyolysis** and **hepatotoxicity**.
*Amiodarone + Atorvastatin*
- **Amiodarone** is a moderate **CYP3A4 inhibitor** and can increase atorvastatin levels, but the inhibition is **less potent** than itraconazole.
- While this combination does carry a risk and requires dose adjustment, the interaction is **less severe** compared to the potent inhibition seen with itraconazole.
- The direct CYP inhibition leading to severe atorvastatin toxicity is less pronounced than with itraconazole.
*Carbamazepine + Atorvastatin*
- **Carbamazepine** is a potent **CYP3A4 inducer**, meaning it would increase the metabolism of atorvastatin, potentially *decreasing* its efficacy rather than causing toxicity through inhibition.
- This interaction would typically lead to subtherapeutic atorvastatin levels, rather than severe toxicity.
*Phenytoin + Atorvastatin*
- **Phenytoin** is also a potent **CYP3A4 inducer**, similar to carbamazepine.
- Concurrent use would likely lead to enhanced metabolism and **reduced efficacy of atorvastatin**, not increased toxicity due to enzyme inhibition.
Drug-Food Interactions Indian Medical PG Question 9: Which of the following statements about hypolipidemic drugs is false?
- A. Gemfibrozil causes myopathy
- B. Gemfibrozil can increase myopathy caused by statins
- C. Lovastatin can cause hepatic dysfunction
- D. Cholesterol reducing drugs are contraindicated in child less than 8 years (Correct Answer)
Drug-Food Interactions Explanation: ***Cholesterol reducing drugs are contraindicated in child less than 8 years***
- While cholesterol-lowering drugs are generally avoided in young children, there are specific **genetic dyslipidemias** where treatment may be initiated earlier under specialist supervision [1].
- The statement is **false** because some genetic conditions may necessitate earlier treatment, making a blanket contraindication for all children under 8 inaccurate [1].
*Gemfibrozil causes myopathy*
- **Gemfibrozil** (a fibric acid derivative) can indeed cause **myopathy**, especially when used alone or in combination with other lipid-lowering agents [2].
- This adverse effect is thought to be due to its mechanism of action affecting fatty acid metabolism and muscle integrity.
*Gemfibrozil can increase myopathy caused by statins*
- The co-administration of **gemfibrozil** with **statins** significantly increases the risk of **myopathy** and **rhabdomyolysis** [2].
- This is primarily due to gemfibrozil inhibiting the **glucuronidation** of statins, which increases statin plasma concentrations [2].
*Lovastatin can cause hepatic dysfunction*
- **Statins**, including **lovastatin**, can cause **elevations in liver transaminases** and, in rare cases, lead to **drug-induced liver injury** [1].
- Regular monitoring of liver function tests is recommended when initiating statin therapy and during follow-up [2].
Drug-Food Interactions Indian Medical PG Question 10: Statins act on:
- A. HMG CoA synthetase
- B. HMG CoA reductase (Correct Answer)
- C. HMG CoA hydratase
- D. Squalene epoxidase
Drug-Food Interactions Explanation: ***HMG CoA reductase*** - **HMG-CoA reductase inhibitors** (statins) are the most effective and widely used class of hypolipidemic agents [1, 2, 3]. - This enzyme is the **rate-limiting step** in cholesterol biosynthesis in the liver [1, 2, 3]. *HMG CoA synthetase* - HMG-CoA synthetase is involved in the synthesis of **HMG-CoA** from acetyl-CoA and acetoacetyl-CoA. - This enzyme precedes the HMG-CoA reductase step and is **not the primary target** for cholesterol-lowering drugs. *Squalene epoxidase* - Squalene epoxidase is an enzyme involved in the later stages of the **cholesterol synthesis pathway**, specifically in converting squalene to squalene epoxide. - While inhibition of this enzyme would reduce cholesterol synthesis, it is **not the main target** of current widely used hypolipidemic agents. *HMG CoA hydratase* - HMG-CoA hydratase (also known as HMG-CoA lyase) is involved in the breakdown of HMG-CoA into **acetyl-CoA and acetoacetate** in ketogenesis. - It is **not directly involved** in the main pathway of cholesterol synthesis that is targeted by current hypolipidemic drugs.
More Drug-Food Interactions Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
